Abstract. We examined the effects of transforming growth factor β 1 (TGF β 1 ) on cellular functions in human lung cancer cell line A549. Treatment of A549 cells with 1 ng/ml TGF β 1 for more than 3 days altered their morphology from an epithelial cobblestone-like appearance to a fibroblastlike one, reduced the expression of E-cadherin mRNA and protein, and induced the formation of F-actin fibers. These hallmarks indicate that TGF β 1 induced the epithelial-mesenchymal transition in A549 cells. Migration of TGF β 1 -treated A549 cells, which was quantified by the wound-healing assay, was markedly accelerated by 3 μ M ATP γ S, a non-hydrolyzable ATP analogue. ATP γ Sinduced migration of TGF β 1 -treated A549 cells was reversed by the P2 antagonist suramin. In contrast, migration of control A549 cells was not altered by ATP γ S. TGF β 1 -treated A549 cells showed an augmentation of ATP-induced Ca 2+ transients, thapsigargin-induced Ca 2+ transients, and store-operated Ca 2+ entry compared with those in control cells. Basal level of the extracellular ATP concentration was significantly lower in TGF β 1 -treated A549 cells than in control cells. We conclude from these results that TGF β 1 augments ATP-induced Ca 2+ mobilization, which leads to the acceleration of migration, in A549 cells but, it markedly reduces endogenous ATP release. This implies that the actions of ATP would become a novel therapeutic target for inhibiting cancer cell migration.
Introduction
Migration of cancer cells requires the transition from an epithelial phenotype to a mesenchymal phenotype. Several soluble factors including transforming growth factor β 1 (TGF β 1 ) have been shown to induce this phenomenon, the epithelial-mesenchymal transition (EMT), in various tumor cells in vitro (1) . EMT endows tumor cells with migration ability (2) , resistance to apoptosis (3) , and properties of cancer stem cells (4) and therefore has been considered as a potential drug target for cancer (5) . It was reported in human lung cancer cell line A549 that TGF β 1 induced EMT, which was assessed by morphological alteration, expression of fibroblastic markers, and a down-regulation of the epithelial marker E-cadherin, via Smad2 activation (6) . Furthermore, Keshamouni et al. (7) reported by using quantitative differential proteomic analysis that the expressions of 51 proteins were altered in A549 cells undergoing EMT by TGF β 1 , of which 29 were up-regulated and 22 were down-regulated. According to their results, the majority of the downregulated proteins were either drug-or nutrient-metabolizing enzymes, and most of the up-regulated proteins such as tropomyosins, filamin A, B, and C, integrin β 1, actin, HSPB1, and non-muscle myosin heavy chain, were the ones involved in cytoskeletal modulation (7) . However, changes of cellular functions, other than the expression of cytoskeletal proteins and the loss of intercellular connection, have not been clarified in tumor cells under-going EMT. If the altered cellular functions were essential for cell motility, these changes would become novel targets for inhibiting cancer metastasis.
Regulated ATP release occurs in most mammalian cells under stressed or stimulated conditions such as mechanical stress (8, 9) , hypoxia (10, 11) , lysophospholipids (12) , and agonist stimulation (9) . Static unstimulated cells also release ATP (13) , and it was shown that the extracellular ATP concentration ([ATP] o ) was three times higher in thyroid cancer cell lines than in normal thyroid cells (14) . Furthermore, in tumor tissues, much larger amount of ATP is released to the extracellular space from tumor cells succumbing to chemotherapy as a result of cell death (15) . Released ATP binds to purinergic receptors and plays physiological and pathophysiological roles in normal tissues, for example, nitric oxide production in endothelial cells (16) and conduction of pain (17) . In cancer cells, released ATP is considered to stimulate cell proliferation in an autocrine manner via purinergic receptors and subsequent multiple downstream signaling pathways (18, 19) . Furthermore, tumor-derived ATP was suggested to contract intratumoral capillaries and enhance the permeability of macromolecules and tumor cells through the capillary wall (20) . Released ATP was also shown to over-express ICAM-1 on lymphatic endothelial cells (LEC) and facilitate the attachment of carcinoma cells to LEC (21) . In contrast to these effects of ATP to promote tumor progression and metastasis, damaged tumor cell-derived ATP is suggested to trigger the activation of inflammasomes in adjacent dendritic cells via purinergic P2RX7 receptor and contribute to the chemotherapy-elicited anticancer immune response (15) .
This study aimed to investigate the possible alteration of cellular functions in A549 cells undergoing EMT. For this purpose, we compared cell migration, Ca 2+ mobilization, and [ATP] o between control and TGF β 1 -treated A549 cells. Obtained results indicate for the first time that ATP markedly accelerates migration of tumor cells after the treatment with TGF β 1 via augmented Ca 2+ mobilization. A possible source of extracellular ATP in tumor tissues is also discussed.
Materials and Methods

Cell culture
A549 cells were purchased from American Type Cell Collection (ATCC) (Manassas, VA, USA), and cultured in Dulbecco's Modified Eagle Medium (DMEM, Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum.
RNA preparation and RT-PCR analysis of E-cadherin mRNA expression
Total RNA was prepared from A549 cells and converted into first strand cDNA by using a commercial kit (RNAqueousTM-4PCR kit; Ambion, Austin, TX, USA). The following primers were used for semi-quantitative RT-PCR analysis (28 cycles) of mRNA expression of E-cadherin: 5′-CGGGAATGCAGTTGAGGATC-3′ (forward) and 5′-AGGATGGTGTAAGCGATGGC-3′ (reverse). Expression of housekeeping GAPDH mRNA was also examined as an internal control using the following primers: 5′-GGGTCATCATCTCTGCACCT-3′ (forward) and 5′-ATCCACAGTCTTCTGGGTGG-3′ (reverse).
Western blotting analysis of E-cadherin protein expression
Expression of E-cadherin protein was assessed with Western blotting by using an enhanced chemiluminescence system (SuperSignal West Dura; Pierce Co., Rockford, IL, USA). Cells with or without treatment with TGF β 1 were lysed, and Western blot analysis for E-cadherin was performed by using polyclonal anti human E-cadherin antibody (Cell Signaling Technology, Danvers, MA, USA). The expression of β -actin protein was assessed as an internal control, using monoclonal anti-β -actin antibody (Sigma, St. Louis, MO, USA). Emitted chemiluminescence was detected and analyzed with FAS-1000 (Toyobo, Osaka).
Staining of actin cytoskeleton
F-actin fibers were examined with a previously reported immunological method (12) using rhodamineconjugated phalloidin (Molecular Probes, Eugene, OR, USA).
Migration assay
Migration of A549 cells was examined with the wound healing assay. A549 cells were seeded on a 35-mm diameter culture dish at a density of 50,000 cells per dish and were cultured for 5 days in the absence or presence of 1 ng/ml TGF β 1 . Confluent cell monolayers were then scratched with a 200 μ l-pipette tip after the pretreatment with 10 μ g/ml mitomycin C for 2 h. Images of the wound surfaces were recorded with a CCD camera (DS-U1; Nikon, Tokyo) that was attached to the microscope (TS100, Nikon) immediately after wounding (0 h) and after culturing for 24 h. Wound widths were then measured with image analysis software (Photoshop; Adobe, San Jose, CA, USA). Since the cells migrated toward the cell-free area from both sides of the wound surface, half of the narrowing of the wound width was regarded as the length of migration. Wound widths of 9 to 12 different wound surfaces per dish were averaged and regarded as one data point.
Measurement of intracellular Ca
] i was measured from A549 cells with fura-2 by using a fluorescence microscopy system (Aquacosmos; Hamamatsu Photonics, Hamamatsu). Cells were cultured on a coverslip in the absence or presence of 1 ng/ml TGF β 1 for 4 to 5 days and were loaded with the acetoxymethylester form of fura-2 (fura-2 AM, 1 μ M, Molecular Probes) for 20 min at 37°C. The coverslip with fura-2 loaded cells was then placed on a chamber of 0.5-ml volume and mounted on an inverted-microscope (IX70; Olympus, Tokyo). The cells were excited with two alternative wavelengths, 340 and 380 nm, and the emitted fluorescent intensities at 505 nm (F 340 and F 380 , respectively) were recorded with a CCD camera (C6790, Hamamatsu Photonics) and calculated into the fluorescence ratio, F 340 /F 380 , as an indicator of [Ca 2+ ] i .
Luciferin-luciferase bioluminescence assay
Extracellular [ATP] o was measured by using luciferinluciferase bioluminescence. A549 cells were seeded on 96-well culture plates at densities of 10,000 cells per well and 30,000 cells per well for the control and TGF β 1 -treated conditions, respectively, and cultured for 5 days before use in the absence or presence of 1 ng/ml TGF β 1 . After the culture medium being carefully removed, the wells were washed with Krebs solution to remove remaining culture medium. Subsequently, 50 μ l of Krebs solution containing 10 mg/ml luciferase-luciferin (Wako Co., Osaka) was added to each well. The emitted luciferin bioluminescence image accumulated for 10 min was then captured with a cooled CCD camera and analyzed with a lumino image analyzer (FAS-1000, Toyobo). Quantified luciferin bioluminescence was then converted into [ATP] o using standard curves of bioluminescence- [ATP] relationships. The number of the cells was manually counted with a hematocytometer after the bioluminescence assay.
Drugs and solutions
The extracellular solution used in the present study was a modified Krebs solution (1.5 mM Ca 2+ solution) containing 132 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl 2 , 1.5 mM CaCl 2 , 11.5 mM glucose, 11.5 mM Hepes; pH adjusted to 7.3 with NaOH. Recombinant human TGF β 1 , neutralizing antibody against TGF β 1 and mitomycin C were obtained from Sigma.
Data analyses
Pooled data were expressed with the mean ± S.E.M. values. Statistical significance was examined with Student's unpaired t -test for comparing two data groups or with repeated measures ANOVA with Bonferroni posthoc test for comparing multiple data sets in migration assay, by using StatView ® (SAS Institute, Cary, NC, USA) for both analyses. Probabilities less than 5% ( P < 0.05) were regarded as significant.
Results
TGFβ 1 -induced EMT in A549 cells
Treatment of A549 cells with 1 ng/ml TGF β 1 for 4 days altered their morphology from cobblestone-like shape into fibroblast-like appearances (Fig. 1A) . Expressions of mRNA and protein of E-cadherin were also reduced in TGF β 1 -treated A549 cells (Fig. 1: B and C) . Furthermore, marked formation of F-actin fibers were observed after the treatment with TGF β 1 for 4 days, while control A549 cells did not show apparent F-actin fibers (Fig. 1D ). These changes were reversed by pre-incubating with blocking anti-TGF β 1 antibody as shown in Fig. 1C . These hallmarks of mesenchymal cell types indicate that TGF β 1 induces EMT in A549 cells. These changes were observed in 3 days after application of TGF β 1 , and maintained at least for 7 days as long as the cells were kept in TGF β 1 (not shown). Thus the present study was performed in A549 cells treated with TGF β 1 for 4 or 5 days.
Increased migration of TGFβ 1 -treated A549 cells by ATPγS
Control A549 cells slightly migrated from the wound surface of the confluent monolayer in 24 h (Fig. 2B) , and non-hydrolysable ATP analogue ATP γ S (3 μ M, Fig. 2 : A and B) and P2 receptor inhibitor suramin (30 μ M, Fig.  2B ) did not alter the migration distance of control cells. TGF β 1 -treated A549 cells showed a significant longer migration than untreated control cells, and ATP γ S (3 μ M) increased the migration of TGF β 1 -treated A549 cells (Fig. 2: A and B) . This was not due to the proliferation of the cells but to the cell migration, because the monolayers were pretreated with 10 μ g/ml mitomycin C for 2 h to inhibit proliferation. Suramin (30 μ M), which did not affect the migration of TGF β 1 -treated A549 cells in the absence of ATP γ S, reversed the effects of ATP γ S on the migration of TGF β 1 -treated A549 cells (Fig. 2: A and  B) . (Fig. 3A) , but net increment of Ca 2+ transients was significantly larger in TGF β 1 -treated cells than in control cells (Fig. 3B) . free solution and subsequent store-operated Ca 2+ entry were significantly larger in TGF β 1 -treated A549 cells than in control cells (Fig. 4: Ab and B) .
ATP-induced
Store depletion-induced
Extracellular [ATP] o in A549 cells
[ATP] o in the static unstimulated condition was significantly lower in TGF β 1 -treated A549 cells (4.0 ± 1.0 nM, n = 10) than in control cells (11.5 ± 1.0 nM, n = 10). Averaged numbers of the cells in the well were 86.7 ± 3.7 × 10 3 and 118.0 ± 4.4 × 10 3 cells for the control and TGF β 1 -treated wells, respectively, since we seeded different number of cells for each condition (control, 10,000 cells; TGF β 1 -treated, 30,000 cells). Therefore, to exclude the possible influence of cell number on the results, we calculated the elevation of [ATP] o per 10 3 cells as 132.6 ± 11.5 and 33.9 ± 8.5 pM for the control and TGF β 1 -treated A549 cells, respectively ( P < 0.05, Fig. 5 ).
Discussion
TGF β 1 induced the morphological change from the cobblestone-like epithelial phenotype to the fibroblastlike mesenchymal appearance in A549 cells (Fig. 1A) , as previously reported (6, 7). Reduction of E-cadherin expression and marked increase in actin fibers further support the induction of EMT in A549 cells by TGF β 1 ( Fig. 1: B, C, and D) . Therefore we consider that the changes of cellular functions observed in this study were those obtained after the cells underwent EMT by TGF β 1 .
It was reported that A549 cells express P2Y2 and P2Y6 purinergic receptors (23, 24) . We found in this study that ATP γ S markedly augments the migration of TGF β 1 -treated A549 cells (Fig. 2) . Augmentation of migration was obtained by stimulating P2 receptors, since the effect of ATP γ S was reversed by suramin, a P2-receptor inhibitor. Therefore, although we used ATP γ S instead of ATP in this assay to avoid the hydrolytic effect of cell surface ectoATPase, continuously supplied ATP would similarly augment the migration of TGF β 1 -treated A549 cells via stimulation of P2 receptors. Although it has been reported that desensitization of P2Y6 receptors is rather slow (25) , prolonged application of ATP γ S may have desensitized the P2 receptors in this assay. Therefore ATP-induced migration would be more prominent in TGF β 1 -treated A549 cells if desensitization of P2 receptors was avoided by intermittent exposure to ATP. Since suramin did not significantly affect the migration of TGF β 1 -treated cells in the absence of ATP γ S, we suppose that ATP does not play an important role in the basal level of migration of TGF β 1 -treated A549 cells. This may also indicate that TGF β 1 -treated A549 cells do not supply significant amount of endogenous ATP to the extracellular space, and this was supported by our observation (Fig. 5) as discussed later. ATP γ S, however, did not stimulate the migration of control A549 cells, and suramin also did not affect the control cell migration (Fig. 2) . Therefore we conclude that ATP accelerates the migration of A549 cells only after the cells underwent EMT.
Intracellular Ca 2+ mobilizing properties play a significant role in the migration of normal epithelial cells and tumor cells (22, 26) . TGF β 1 -treated A549 cells markedly augmented the ATP-induced Ca 2+ responses (Fig. 3) , without affecting the threshold concentration of ATP. We also observed that thapsigargin-induced initial Ca ] i were significantly larger in TGF β 1 -treated cells than in control cells (Fig. 4) . Store-operated Ca 2+ entry is activated by the depletion of intracellular Ca 2+ stores, and the refilling state of the Ca 2+ stores is considered to be maintained by store-operated Ca 2+ entry (27) . The activation of store-operated Ca 2+ entry may therefore play a key role in the altered Ca 2+ responses in A549 cells after (31) . Furthermore, it has been reported that cytoskeletons and their regulators, including actin (32), cofilin (33) , tubulin (34) , and myosin light chain kinase (35) , are involved in the cellular mechanisms of storeoperated Ca 2+ entry. According to proteome analysis of control and TGF β 1 -treated A549 cells, various proteins involved in cytoskeletal modulations were up-regulated in A549 cells undergoing EMT (7). Actually we observed the marked activation of actin cytoskeleton in TGF β 1 -treated A549 cells (Fig. 1D) . In contrast, the expressions of Ca 2+ -entry channels (Orai1 and TRPC channels) and Ca 2+ -sensor (STIM1) were not reported to be altered by TGF β 1 in A649 cells (7) . Therefore, we consider that the treatment with TGF β 1 leads to the activation of Ca 2+ -mobilizing properties mainly due to cytoskeletal modulation in A549 cells.
We observed that the net elevation of [ATP] o per 10 3 cells was three times higher in untreated control A549 cells than in TGF β 1 -treated cells (Fig. 5) . So it seems unlikely that TGF β 1 -treated cells induce autocrine ATP release sufficient for the activation of their own migration. It is supposed that the majority of the cancer cell population is non-EMT 'epithelial' cells in tumor tissues (1) . Therefore we suppose that the cells other than TGF β 1 -stimulated cells, including non-EMT epithelial tumor cells, would be the main source of extracellular ATP for migration in vivo. Tumor cell-derived ATP has been suggested to play roles in tumor cell proliferation (19) , intratumoral endothelial leakage (20) , and adhesion of tumor cells to LECs (21) . Although damaged cell-derived ATP may show favorable effects on anticancer immunity via P2RX7 receptors on dendritic cells (15) , direct effects of endogenous ATP on A549 cell via P2Y receptors would be tumor-promoting, by stimulating cell proliferation (23) and migration (present study).
In conclusion, we have shown for the first time that extracellular ATP plays a significant role in the migration of A549 cells after the induction of EMT with TGF β 1 . Further studies are warranted to determine whether or not the release of ATP from control tumor cells and the action of ATP on migrating cells would become a novel approach for the inhibition of cancer metastasis. 
